17.11.2012 • NewsFTCUSAValeant

U.S. FTC Clears Valeant Deal for Medicis Pharmaceutical

The U.S. Federal Trade Commission has cleared Valeant Pharmaceuticals International's $2.6 billion deal to buy U.S. dermatology rival Medicis Pharmaceutical, without conditions, Valeant said on Friday.

The combined company is set to dominate the U.S. dermatology market. Medicis led that market in gross sales in 2011, while Valeant, Canada's biggest public drugmaker, ranked third, Valeant said when the deal was first announced.

Last December, when the FTC approved Valeant's acquisitions of the dermatology units of Sanofi and Johnson & Johnson, it forced the firm to sell off the rights to three drugs.

Valeant, on the acquisition trail since its 2010 takeover by Biovail, which assumed the Valeant name, has favored segments where patients often pay out of pocket, such as ophthalmology and dermatology, cutting its exposure to cost-sensitive insurers.

Medicis' products include Solodyn, a prescription acne tablet, Restylane, an injectable filler, and Dysport, a competitor to Allergan's Botox anti-wrinkle treatment.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.